Detection of Beet curly top virus in Solanum jamesii, Artemisia tridentata, Helianthus annuus, and Cannabis sativa in Utah.

Historically, beet curly top virus (BCTV; Geminiviridae, Curtovirus) is known for destroying the sugar beet industry in Utah and has been a persistent problem in the state since then (Ball, 1917). Starting in June of 2022, we began identifying plants in San Juan County, Utah with chlorosis and leaf curling. Of note, Solanum jamesii, the Four Corners potato, Artemisia tridentata, big sagebrush, and Helianthus annuus, common sunflower, were found with general chlorosis, severe leaf curling and in the case of the sage brush, completely lacking in smell whereas nearby sage plants without the yellowing were intensely fragrant. In August 2023, Cannabis sativa plants for hemp production were found with severe leaf curling in Juab County, Utah. Samples were collected and stored at -80°C for future work. DNA was extracted using the IBI Genomic Plant DNA kit (IBI Scientific, Dubuque, IA) and subjected to rolling circle amplification using Phi29 polymerase (NEB, Ipswich, MA). The primer set BCTV2 (Strausbaugh et al. 2008) for BCTV detection was then used on a subset of the RCA-positive samples for either one (A. tridentata, H. annus, and S. jamesii) or two (C. sativa) plants displaying classic BCTV symptoms, to amplify a 518 bp region. This amplicon was then sequenced by the Sanger method to a 4x coverage. The resulting sequences (accession nos. OR698900 to OR698904) share 98.94 to 99.80% nucleotide identity to the Worland strain (accession no. KU892789.1) for all samples. To confirm the detection, a triple antibody sandwich ELISA kit from Nano Diagnostics (San Jose, CA) was used on these, and other plants of similar species and symptoms from across the state. Samples that tested positive include 3/3 symptomatic H. annuus plants, 1/1 symptomatic S. jamesii, 3/3 symptomatic A. tridentata. The A. tridentata samples were collected from Juab, San Juan, and Utah Counties. None of three asymptomatic A. tridentata plants tested were ELISA positive. Of the C. sativa plants tested by ELISA, 9/9 of the plants displaying classic BCTV symptoms in that host were positive and 6/6 of the plants without classic BCTV symptoms were ELISA positive. The findings of these novel hosts indicate the need for increased testing and analysis of economically relevant crops and native flora across the state. These findings represent a concern for conservation in the case of S. jamesii and a potential threat to the growing hemp industry in the state due to the severity of BCTV symptoms on these plants. Additionally, the finding of A. tridentata as a host may represent a significant finding for the epidemiology of BCTV in the Mountain West region as A. tridentata is distributed from Mexico to Canada along the Rocky Mountain range and is found in much of the Western US in arid regions. This is the first report, to our knowledge, of S. jamesii and A. tridentata as hosts for BCTV and the first peer reviewed reports for H. annuus and C. sativa as hosts for BCTV in Utah.

Expansion of the Genotypic and Phenotypic Spectrum of ASH1L-Related Syndromic Neurodevelopmental Disorder.

Pathogenic ASH1L variants have been reported in probands with broad phenotypic presentations, including intellectual disability, autism spectrum disorder, attention deficit hyperactivity disorder, seizures, congenital anomalies, and other skeletal, muscular, and sleep differences. Here, we review previously published individuals with pathogenic ASH1L variants and report three further probands with novel ASH1L variants and previously unreported phenotypic features, including mixed receptive language disorder and gait disturbances. These novel data from the Brain Gene Registry, an accessible repository of clinically derived genotypic and phenotypic data, have allowed for the expansion of the phenotypic and genotypic spectrum of this condition.

The Brain Gene Registry: a data snapshot.

Monogenic disorders account for a large proportion of population-attributable risk for neurodevelopmental disabilities. However, the data necessary to infer a causal relationship between a given genetic variant and a particular neurodevelopmental disorder is often lacking. Recognizing this scientific roadblock, 13 Intellectual and Developmental Disabilities Research Centers (IDDRCs) formed a consortium to create the Brain Gene Registry (BGR), a repository pairing clinical genetic data with phenotypic data from participants with variants in putative brain genes. Phenotypic profiles are assembled from the electronic health record (EHR) and a battery of remotely administered standardized assessments collectively referred to as the Rapid Neurobehavioral Assessment Protocol (RNAP), which include cognitive, neurologic, and neuropsychiatric assessments, as well as assessments for attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Co-enrollment of BGR participants in the Clinical Genome Resource's (ClinGen's) GenomeConnect enables display of variant information in ClinVar. The BGR currently contains data on 479 participants who are 55% male, 6% Asian, 6% Black or African American, 76% white, and 12% Hispanic/Latine. Over 200 genes are represented in the BGR, with 12 or more participants harboring variants in each of these genes: CACNA1A, DNMT3A, SLC6A1, SETD5, and MYT1L. More than 30% of variants are de novo and 43% are classified as variants of uncertain significance (VUSs). Mean standard scores on cognitive or developmental screens are below average for the BGR cohort. EHR data reveal developmental delay as the earliest and most common diagnosis in this sample, followed by speech and language disorders, ASD, and ADHD. BGR data has already been used to accelerate gene-disease validity curation of 36 genes evaluated by ClinGen's BGR Intellectual Disability (ID)-Autism (ASD) Gene Curation Expert Panel. In summary, the BGR is a resource for use by stakeholders interested in advancing translational research for brain genes and continues to recruit participants with clinically reported variants to establish a rich and well-characterized national resource to promote research on neurodevelopmental disorders.

Generating Clinical-Grade Gene-Disease Validity Classifications Through the ClinGen Data Platforms.

Clinical genetic laboratories must have access to clinically validated biomedical data for precision medicine. A lack of accessibility, normalized structure, and consistency in evaluation complicates interpretation of disease causality, resulting in confusion in assessing the clinical validity of genes and genetic variants for diagnosis. A key goal of the Clinical Genome Resource (ClinGen) is to fill the knowledge gap concerning the strength of evidence supporting the role of a gene in a monogenic disease, which is achieved through a process known as Gene-Disease Validity curation. Here we review the work of ClinGen in developing a curation infrastructure that supports the standardization, harmonization, and dissemination of Gene-Disease Validity data through the creation of frameworks and the utilization of common data standards. This infrastructure is based on several applications, including the ClinGen GeneTracker, Gene Curation Interface, Data Exchange, GeneGraph, and website.